{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:18:51Z","timestamp":1765819131886,"version":"3.48.0"},"reference-count":12,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,5,2]]},"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriasis vulgaris often leads to a significant impaired quality of life and dissatisfaction with the existing therapeutic approaches. However, patients\u2019 quality of life and treatment satisfaction are of utmost importance, since it is positively related to therapy adherence and encourages patient\u2019s compliance. The study described herein evaluates the quality of life, treatment satisfaction and efficacy during the initial 6\u2009months of treatment with a non-biological systemic agent in a real-life clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This observational study compares quality of life, treatment satisfaction and the efficacy of non-biological systemic therapy between 60 patients suffering from plaque psoriasis receiving the non-biological systemic therapies with apremilast, methotrexate and fumaric acid esters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was provided by the ethics committee of the medical faculty of the University of Heidelberg. Ethics approval number is S-298\/2015. The design and the final results of the study will be published and made available to the public.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      German Clinical Trial Register (DRKS): DRKS00008721 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.germanctr.de\/\">https:\/\/www.germanctr.de\/<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-014279","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T14:51:31Z","timestamp":1500303091000},"page":"e014279","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: study protocol for a prospective observational study"],"prefix":"10.1136","volume":"7","author":[{"given":"Christine","family":"Fink","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo E","family":"Schank","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Trenkler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"issue":"Suppl 2","key":"2025121509150788000_7.6.e014279.1","first-page":"S1","article-title":"S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update","volume":"10","author":"Nast","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025121509150788000_7.6.e014279.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"2025121509150788000_7.6.e014279.3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1958.01560080060010"},{"key":"2025121509150788000_7.6.e014279.4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/2229-5178.86007","article-title":"Fumaric acid esters in dermatology","volume":"2","author":"Wollina","year":"2011","journal-title":"Indian Dermatol Online J"},{"key":"2025121509150788000_7.6.e014279.5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","article-title":"Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III efficacy and\u00a0safety trial evaluating theeffects of apremilast in psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis","volume":"75","author":"Bissonnette","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025121509150788000_7.6.e014279.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"2025121509150788000_7.6.e014279.7","first-page":"581","article-title":"Patients with psoriasis and their compliance with medication","volume":"41","author":"Richards","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2025121509150788000_7.6.e014279.8","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"2025121509150788000_7.6.e014279.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2025121509150788000_7.6.e014279.10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025121509150788000_7.6.e014279.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025121509150788000_7.6.e014279.12","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: BMJ Publishing Group, 2015. https:\/\/www.R-project.org\/"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-014279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:15:14Z","timestamp":1765818914000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-014279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,30]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1136\/bmjopen-2016-014279"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-014279","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}